The Difference Between Cystatin C- and Creatinine-Based eGFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF

• Published in: American journal of kidney diseases
• Main Authors: Pinsino, Alberto, Carey, Matthew R, Husain, Syed, Mohan, Sumit, Radhakrishnan, Jai, Jennings, Douglas L, Nguonly, Austin S, Ladanyi, Annamaria, Braghieri, Lorenzo, Takeda, Koji, Faillace, Robert T, Sayer, Gabriel T, Uriel, Nir, Colombo, Paolo C, Yuzefpolskaya, Melana
• Format: Journal Article
• Language: English
• Published: United States 20-04-2023
• Subjects: heart failure; reduced ejection fraction; kidney function; estimated glomerular filtration rate; Cystatin C
• ISSN: 1523-6838

The clinical implications of the discrepancy between cystatin C (cysC)- and serum creatinine (Scr)-estimated glomerular filtration rate (eGFR) in patients with heart failure (HF) and reduced ejection fraction (HFrEF) are unknown.
Post-hoc analysis of randomized trial data.
1,970 patients with HFrEF enrolled in PARADIGM-HF with available baseline cysC and Scr measurements.
Intraindividual differences between eGFR based on cysC (eGFR
) and Scr (eGFR
; eGFRdiff
).
Clinical outcomes included the PARADIGM-HF primary end point (composite of cardiovascular [CV] mortality or HF hospitalization), CV mortality, all-cause mortality, and worsening kidney function. We also examined poor health-related quality of life (HRQoL), frailty, and worsening HF (WHF), defined as HF hospitalization, emergency department visit, or outpatient intensification of therapy between baseline and 8-month follow-up.
Fine-Gray subdistribution hazard models and Cox proportional hazards models were used to regress clinical outcomes on baseline eGFRdiff
. Logistic regression was used to investigate the association of baseline eGFRdiff
with poor HRQoL and frailty. Linear regression models were used to assess the association of WHF with eGFR
, eGFR
, and eGFRdiff
at 8-month follow-up.
Baseline eGFRdiff
was higher than +10 and lower than-10mL/min/1.73m
in 13.0% and 35.7% of patients, respectively. More negative values of eGFRdiff
were associated with worse outcomes ([sub]hazard ratio per standard deviation: PARADIGM-HF primary end point, 1.18; P=0.008; CV mortality, 1.34; P=0.001; all-cause mortality, 1.39; P<0.001; worsening kidney function, 1.31; P=0.05). For a 1-standard-deviation decrease in eGFRdiff
, the prevalences of poor HRQoL and frailty increased by 29% and 17%, respectively (P≤0.008). WHF was associated with a more pronounced decrease in eGFR
than in eGFR
, resulting in a change in 8-month eGFRdiff
of-4.67mL/min/1.73m
(P<0.001).
Lack of gold-standard assessment of kidney function.
In patients with HFrEF, discrepancies between eGFR
and eGFR
are common and are associated with clinical outcomes, HRQoL, and frailty. The decline in kidney function associated with WHF is more marked when assessed with eGFR
than with eGFR
.
Kidney function assessment traditionally relies on serum creatinine (Scr) to establish an estimated glomerular filtration rate (eGFR). However, this has been challenged with the introduction of an alternative marker, cystatin C (cysC). Muscle mass and nutritional status have differential effects on eGFR based on cysC (eGFR
) and Scr (eGFR
). Among ambulatory patients with heart failure enrolled in PARADIGM-HF, we investigated the clinical significance of the difference between eGFR
and eGFR
. More negative values (ie, eGFR
>eGFR
) were associated with worse clinical outcomes (including mortality), poor quality of life, and frailty. In patients with progressive heart failure, which is characterized by muscle loss and poor nutritional status, the decline in kidney function was more pronounced when eGFR was estimated using cysC rather than Scr.